Skip to content
2000
Volume 17, Issue 5
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

A clear link exists between the extension of life expectancy throughout the world and the increased incidence of age-related neurodegenerative disorders. Diseases like Alzheimer’s and Parkinson’s are chronic diseases with devastating consequences for patients and their families. They also represent a major economic cost for society. Therapeutic progress has been made mainly by alleviating some of the symptoms of these diseases, but currently no cure is available. Attempts to develop new therapies have been hampered mainly because of gaps in our current knowledge about the pathogenic mechanism underlying neurodegeneration, making difficult the identification of targets for new drug development, and also because of the lack of biomarkers essential for early diagnosis, patient stratification and follow up of treatment. Taking advantage of the latest technical developments, proteomics and peptidomics based approaches are being used to identify new cellular pathophysiological pathways as well as biomarkers in biological fluids. Here we will review the results, mainly published in the last five years, of unbiased proteomics and peptidomics approaches for biomarker research using biological fluids of Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis patients.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/138920101705160303165719
2016-04-01
2025-01-27
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/138920101705160303165719
Loading

  • Article Type:
    Research Article
Keyword(s): biomarkers; mass spectrometry; Neurodegenerative diseases; peptidomics; proteomics
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test